|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 48, 139-144, January 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology






* Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Department of Clinical Pharmacology, University of Bonn, Bonn, Germany
Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, UK
** Medical Research Council Epidemiology Unit, Cambridge, UK

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
Published, JLR Papers in Press, October 30, 2006.
1 S. Pinedo and M. N. Vissers contributed equally to this work. ![]()
2To whom correspondence should be addressed. e-mail: m.n.vissers{at}amc.uva.nl
| ABSTRACT |
|---|
|
|
|---|
Supplementary key words sitosterol campesterol cholesterol humans European Prospective Investigation into Cancer and Nutrition
| INTRODUCTION |
|---|
|
|
|---|
The usual daily intake of plant sterols in Western diets varies between 150 and 350 mg/day (2). In contrast to cholesterol, plant sterols cannot be synthesized in animals; they are derived exclusively from vegetables and vegetable oils and are thought to have cellular functions in these organisms that are similar to those of cholesterol in animals (3). In Western society,
1,2001,700 mg of cholesterol, of which approximately one-fourth is of dietary origin, enters the lumen of the small intestine every day (3). Approximately 50% of this cholesterol load is absorbed (4, 5), whereas for plant sterols this percentage ranges from merely 5% to sometimes 18%, depending on the type of sterol (6, 7).
The lower net absorption of plant sterols compared with cholesterol is attributable to the active resecretion of plant sterols back into the enteric lumen. This process is mediated by the ATP binding cassette (ABC) half-transporters ABCG5 and ABCG8 (8, 9). In individuals with dysfunctional ABCG5 and/or ABCG8, plant sterol net absorption is increased, resulting in 50-fold increased plasma levels of plant sterols. In patients with this rare inherited autosomal recessive disorder sitosterolemia, sitosterol levels range between 10 and 30 mg/dl (10), whereas in normal subjects, these levels seldom exceed 1 mg/dl (3). Phenotypical signs found in such patients with sitosterolemia are much like those of inherited hypercholesterolemia, i.e., development of xanthomas and premature coronary disease (8, 9, 11). These latter observations have led to the hypothesis that high levels of plant sterols are atherogenic.
In contrast, dietary plant sterols are currently being added to several food products for their reducing effect on plasma cholesterol levels. They compete with cholesterol for incorporation into micelles and thereby reduce cholesterol absorption in the intestine. Plasma levels of low density lipoprotein cholesterol (LDL-C) are reduced by
10% as a consequence of foods enriched in plant sterols (12). However, consumption of such foods will also increase plasma plant sterol levels (13, 14), notwithstanding the fact such levels remain low compared with those in sitosterolemia patients. It is unclear whether such slightly increased plasma plant sterol concentrations over protracted periods of time, either physiologically or caused by plant sterol-enriched foods, constitute an additional risk factor for atherosclerosis.
Some studies have suggested that increased plasma plant sterol levels are associated with coronary artery disease (CAD) (1518), but another study did not reveal any association with surrogate markers of atherosclerosis (19). Because the data are not consistent and data from prospective studies are limited, we examined the association between plasma levels of plant sterols and the risk of future CAD in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort, comprising apparently healthy men and women who had never suffered a myocardial infarction or stroke.
| METHODS |
|---|
|
|
|---|
The design and methods of the study have been described previously in detail (20). In short, eligible participants were recruited by mail. At the baseline survey between 1993 and 1997, participants completed a detailed health and lifestyle questionnaire. Blood was taken by venipuncture into plain and citrate bottles. Blood samples were processed for assay at the Department of Clinical Biochemistry, University of Cambridge, or stored at 80°C. All individuals have been flagged for death certification at the UK Office of National Statistics, with vital status ascertained for the entire cohort. In addition, participants admitted to the hospital were identified using their unique National Health Service number by data linkage with ENCORE, the East Norfolk Health Authority database, which identifies all hospital contacts throughout England and Wales for Norfolk residents. Participants were identified as having CAD during follow-up if they had a hospital admission and/or died with CAD as the underlying cause. CAD was defined as codes 410 to 414 according to the International Classification of Diseases, 9th revision. We report results with follow-up to January 2003, an average of
6 years. The study was approved by the Norwich District Health Authority Ethics Committee, and all participants gave signed informed consent.
Participants
For this analysis, we only considered individuals who did not report a history of heart attack or stroke at the baseline clinic visit. Of those individuals, 373 cases, in whom fatal or nonfatal CAD developed during follow-up, were randomly selected. Controls (758) were study participants who remained free of CAD during follow-up. Two controls were matched to each case by sex, age (within 5 years), and time of enrollment (within 3 months).
Biochemical analyses
Serum levels of total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglycerides were measured on fresh samples with the RA 1000 (Bayer Diagnostics, Basingstoke, UK), and LDL-C levels were calculated with the Friedewald formula (21). In 2005, plasma samples for cases and controls were retrieved from frozen storage. The plasma noncholesterol sterols sitosterol, campesterol, and lathosterol were hydrolyzed, extracted, and analyzed as trimethylsilyl ethers by gas-liquid chromatography (Hewlett Packard 5890) using an automatic injection system (Hewlett Packard Automatic Sampler 7673A) with 5
-cholestane as the internal standard (22). Because noncholesterol sterols are transported in serum by lipoproteins, changes in lipoprotein concentrations also affect concentrations of noncholesterol sterols (23). Therefore, noncholesterol sterols are expressed in concentrations (mg/dl) as well as in ratios to cholesterol (µg/mg). To calculate the noncholesterol sterol-to-cholesterol ratios adequately, cholesterol levels were also analyzed by gas-liquid chromatography in the same run as the noncholesterol sterols.
Samples were analyzed in random order to avoid systemic bias. Researchers and laboratory personnel had no access to identifiable information and could identify samples by number only.
Statistical analysis
Baseline characteristics were compared between cases and controls using the GENMOD procedure of SAS (SAS Institute, Inc., Cary, NC), taking into account the matching between them. Data with a skewed distribution were first log-transformed, but in the tables we show untransformed medians and corresponding interquartile ranges (IQRs) or the distribution across tertiles for plant sterols.
To determine relationships between plant sterols and traditional cardiovascular risk factors, mean risk factor levels were calculated per sitosterol or campesterol tertile. Tertiles were based on the distribution in controls. The linearity between risk factor levels and plant sterol tertiles was calculated with the General Linear Models procedure in SAS. The GENMOD procedure was used for logistic regression analysis to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) as estimates of the relative risk of incident CAD, adjusted for matching variables. The lowest tertile was used as the reference category. ORs were adjusted for the following cardiovascular risk factors: age, sex, systolic blood pressure, total cholesterol, HDL-C, body mass index (BMI), smoking (never, past, current), and diabetes. ORs were also estimated after additional adjustment for the lathosterol concentration, a marker for cholesterol synthesis. ORs based on the plant sterol-to-cholesterol ratios were additionally adjusted for the lathosterol-to-cholesterol ratio instead of the lathosterol concentration. P < 0.05 was considered significant. Statistical analyses were computed with SAS software, version 9.1.
| RESULTS |
|---|
|
|
|---|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The hypothesis that plasma plant sterol levels may be atherogenic has been supported by a few previous studies (1518, 24). Glueck et al. (15) measured plant sterol concentrations in nonsitosterolemic individuals and concluded that plant sterols are associated with a personal or family history of CAD in subjects younger than 55 years. However, only individuals with hypercholesterolemia, who are already at higher risk, were included, and it is difficult to disentangle the atherogenic effect of cholesterol versus plant sterols in that study. A nested case-control study from the original Prospective Cardiovascular Munster Study among only men (n = 477) showed that subjects with increased sitosterol levels had a 1.8-fold risk of major coronary events compared with subjects with low sitosterol levels. Moreover, in men with a >20% coronary event risk over 10 years, high sitosterol levels were associated with an additional 3-fold increase in risk (17). However, only univariate analysis was performed, and it is unclear whether the positive association between plasma sitosterol levels and coronary events would have remained significant if multivariate analyses had been performed to adjust for potential confounders. Finally, recent findings in the Framingham Offspring Study also showed a significant association between plant sterol-to-cholesterol ratios and CAD (24). However, in that cohort, lipids and lipoproteins were not associated with CAD, which could cast doubts on the validity of the selection of cases and controls. In summary, even though some studies have suggested a positive association between plant sterol levels and CAD risk, these data should be interpreted with caution.
Our findings indicate that plant sterols are not associated with CAD risk, consistent with the results described by Wilund and coworkers (19). They investigated a possible relation between plant sterol-to-cholesterol ratios and coronary atherosclerosis by measuring coronary calcium with electron beam computed tomography scanning in the Dallas Heart Study. They found no difference in median plasma sitosterol and campesterol ratios between subjects with and without positive calcium scores, and there was no correlation between plasma levels of plant sterols and the amount of electron beam computed tomography-detected calcium. Thus, our findings, showing no positive association between plasma plant sterol ratios and clinical cardiovascular end points in a nested case-control analysis from a large prospective study, endorse the findings of Wilund and colleagues (19), which were based on a surrogate marker of CAD.
In our study, sitosterol levels unexpectedly tended to be inversely associated with CAD risk, in contrast to the positive association found by others (1518, 24). Even though this finding may be surprising, all other associations between plant sterol levels and traditional CAD risk factors, as well as those between traditional risk factors and CAD risk, were in the expected direction. For instance, levels of total cholesterol, LDL-C, triglycerides, systolic and diastolic blood pressure, and BMI were significantly higher, whereas HDL-C levels were significantly lower in cases than in controls. Also, as reported previously (18, 25), the sitosterol and campesterol concentrations and their ratios to cholesterol were inversely correlated with BMI, plasma triglycerides, and lathosterol concentrations, a marker of cholesterol synthesis (2). Furthermore, the plasma sitosterol and campesterol levels and their ratios to cholesterol were in the same range as shown in previous studies (1519). For instance, median plasma sitosterol and campesterol levels were 0.21 and 0.32 mg/dl, respectively. Those concentrations correspond with those reported in other studies, in which mean plasma sitosterol and campesterol concentrations ranged from 0.17 to 0.40 mg/dl and from 0.21 to 0.50 mg/dl, respectively (1518). These identical plant sterol concentrations and associations with traditional risk factors of CAD in this study compared with previous studies strengthen the reliability of our data, which indicate that plant sterol levels are not associated with CAD risk, at least not positively.
Consumption of food products enriched with plant sterols has been shown to reduce cholesterol absorption and thereby plasma LDL-C levels. Clinical trials have shown that an intake of 23 g/day plant sterols significantly reduces serum LDL-C concentrations from 9% to 14% (12, 26). They do so by reducing the absorption of cholesterol from the intestine by competing with cholesterol for incorporation into mixed micelles, the latter being essential for the transport of sterols to and their uptake by mucosal cells. Total concentrations of plant sterols in plasma in subjects consuming sterol ester products are within the range of 0.62.0 mg/dl (13, 14). Although this is 20 to 100 times lower than in patients homozygous for sitosterolemia, some concerns have been raised that the increase in plasma plant sterol levels attributable to the use of plant sterol-enriched food products as a cholesterol-lowering agent may in fact be atherogenic. Our study cannot address this issue, because the participants did not use food products enriched with plant sterols. However, based on our data, we speculate that it is unlikely that such small concentrations of plasma plant sterols are detrimental, especially when taking the cholesterol-lowering effect of such food products into account.
A number of issues have to be taken into account when interpreting the results of our study. First, CAD events were ascertained through death certification and hospital admission data, which are likely to lead to both underascertainment and misclassification of cases. However, previous validation studies in our cohort indicate high specificity of such case ascertainment (27), which was at least equivalent to that of other large prospective cohort studies. Second, we cannot exclude the possibility that sample storage at 80°C for 10 years may have affected the plant sterol concentrations of plasma in the tubes. However, data on 10 year stability of plant sterols in frozen plasma are lacking. Nonetheless, plant sterol concentrations in our cohort were comparable to those in previous studies (15, 17, 28); hence, a loss of plant sterols during storage seems unlikely. Finally, plasma levels of plant sterols were determined in a single sample that was obtained from nonfasting subjects and at a nonuniform time of the day. Diurnal variation and variation over time could have affected the plant sterol concentrations. However, intraindividual variation in the plasma concentrations of noncholesterol sterols is minimal (29). Furthermore, the half-lives of sitosterol and campesterol are 3 and 4 days, respectively, and excessive variation during the day is not expected (30, 31). Therefore, it is unlikely that variation over time would have influenced our results.
We conclude that slightly increased plasma levels of plant sterols, at least in the physiological range, are not positively associated with the risk of CAD and do not appear to be adversely related to CAD in apparently healthy individuals. Within this range, these findings provide reassurance for the safe addition of plant sterols to food products.
| ACKNOWLEDGMENTS |
|---|
Manuscript received August 18, 2006 and in revised form October 20, 2006.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves J. Lipid Res., July 1, 2008; 49(7): 1511 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Miettinen and H. Gylling Vascular effects of diets, especially plant sterol ester consumption. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1562 - 1563. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |